“…Therapeutic cancer vaccines, including sipuleucel-T, PROSTVAC, and personalized peptide vaccines, have not led to significant survival differences in patient populations [ 34 , 35 , 36 ]. Newer trials combining vaccines and other agents, the immune response, and ICIs may be able to downgrade the tumor defenses against T cells [ 37 , 38 , 39 , 40 ]. Sipuleucel-T did, however, lead to differences in T cells that were thrice activated in vaccinated patients as compared to placebo groups; therefore, the vaccine may prime patients’ immune response [ 41 , 42 , 43 , 44 ].…”